Autologous Broadspectrum Human Tumor Antibody

Gipsitumab ^TM is based on the discovery by NIT that adult human stem cells can be harvested noninvasively and converted to generate antibodies against human tumors. The process involves the isolation of exfoliated transit stem cells (GipCTM, gastrointestinal progenitor stem cells) and converting them to lineage-directed IgG secreting cells that  recognize native tumor antigens. GipsitumabTM induces 100% cell death in several cancer cell lines (both solid tumors and leukemias) in vitro, but has no effect on normal epithelial cells. The in vivo efficacy of this product in tumor growth inhibition was demonstrated in nude mice carrying human colon adenocarcinoma xenograft. This technology has the potential to be an effective personalized anti-tumor therapy where the patient donates the GipCTM cells from which antibodies are generated to combat the patients own tumor.

Applications include:

Method to generate autologous antibodies to treat and selectively target the patient's cancer with limited toxicity.
Method to accurately diagnose and treat with anti-tumor therapeutic vaccines
Method to develop early noninvasive screening tests for common cancers (colon, breast and lung)